Emerging evidence has consistently demonstrated that sodium-glucose cotransporter 2 (SGLT2) inhibitors significantly reduce the risk of HF hospitalization and cardiovascular (CV) death among patients with HF and preserved ejection fraction (HFpEF) or reduced ejection fraction (HFrEF).1,2,3,4,5 These findings have been incorporated into the 2021 European Society of Cardiology guidelines for diagnosing and treating acute and chronic HF6 and then the 2022 American Heart Association/American College of Cardiology/Heart Failure Society of America guideline for the management of HF.7 Here, SLC5A2 is linked to heart failure.